INCHEON, South Korea, April 14, 2025 /– Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). Yuflyma is an FDA-approved…Original Article
FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion’s Biosimilar to Humira (adalimumab)
